Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390061 | 0.84 | DHFR (0.66) | DHFRDCPSKCNH2 | |
| SCHEMBL30912751 | 0.84 | DHFR (0.66) | DHFRDCPSKCNH2 | |
| SCHEMBL21497071 | 0.81 | HTT (0.46) | DHFRGAADCPSHTTKCNH2 | |
| SCHEMBL29378492 | 0.81 | HTT (0.46) | DHFRGAADCPSHTTKCNH2 | |
| SCHEMBL21497074 | 0.81 | ACHE (0.44) | DHFRACHEDCPSPARP1HTT | |
| SCHEMBL3337344 | 0.79 | PARP1 (0.44) | DHFRGRIN1GRIN2AACHEBCHE | |
| SCHEMBL30013654 | 0.79 | PARP1 (0.44) | DHFRGRIN1GRIN2AACHEBCHE | |
| SCHEMBL8899181 | 0.77 | DCPS (0.71) | DHFRACHEDCPSKCNH2 | |
| SCHEMBL29344541 | 0.76 | PARP1 (0.42) | GRIN1GRIN2AACHEBCHEPARP1 | |
| SCHEMBL17158157 | 0.73 | DHFR (0.46) | DHFRGAAGRIN1GRIN2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | ADRB1, ADRB2, ADRA2B | DHFR 2861/4885GAA 4302/4885GRIN1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.